BMAC – Biopharmaceutical Manufacturer's Advisory Council
An initiative by leading Biopharmaceutical companies in the world to establish Singapore as the country of choice for global biomedical sciences manufacturing.
Roche today proudly commemorates its 50th anniversary of operations in Singapore. This milestone is being marked with a celebratory event attended by Mr. Ong Ye Kung, Minister for Health of Singapore and Dr. Thomas Schinecker, CEO of the Roche Group.
Roche Singapore started in a modest office on Shenton Way in 1973 and has grown into a local leader in diagnostics and innovative medicines across multiple disease areas. Today, Roche Singapore employs more than 1,000 people across its pharmaceuticals, diagnostics and manufacturing divisions.
The ties between Roche and Singapore run deep. We have grown together for more than 50 years. Singapore was Roche’s first site for biologics manufacturing in Asia and today we run not one, but two plants here. Singapore is also home to the regional headquarters of our diagnostics business and is a major hub for our pharmaceuticals division. This is testament to what can be achieved when public and private sectors work together for the long term benefit of people in Singapore.
Focus on long-term partnerships
Looking ahead, long-term public-private partnerships (PPPs) will be a central focus for Roche Singapore – both deepening existing relationships and forging new ones. Tangible benefits have already been achieved with long-term PPPs such as the ARiSE Patient Support Programme and FlexCare collaborations with Singapore public healthcare institutions, and the partners are studying their future evolution.
Roche also remains committed to PPPs in their earlier stages, such as the research partnership with the Singapore Translational Cancer Consortium to build a local clinico- genomic database for precision oncology.
Supporting local health innovation
Innovation has and will be the driving force for Roche Singapore in the future. Singapore is already the APAC base for Startup Creasphere, Roche’s global digital health innovation accelerator, which has supported four Singapore-based startups since its inception in 2020.
Last year, Roche and the National Health Innovation Centre (NHIC) announced an open innovation partnership to explore collaboration opportunities for clinically and commercially impactful healthtech projects from an early stage.
It is also working with various APAC ecosystem stakeholders to co-develop In-Co Hub, a new APAC hub for healthcare innovation. In-Co Hub will serve as an open innovation platform for Roche to partner with government agencies, venture capitals, accelerators and startups to bring promising innovations to market. With Startup Creasphere and In-Co Hub, Roche aims to accelerate adoption and scaling of biomedical innovation across the APAC region.
Site Heads / General Managers / Vice Presidents from 24 Sites across the BMAC Community came together to sign the BMAC Vision Zero Pledge on
Three BMAC companies were proud recipients of the WSH CARE Award, a prestigious recognition presented by the Ministry of Manpower (MOM) and the Workplace Safety
The Singapore Eye Research Institute (SERI) and Santen Pharmaceutical Co., Ltd., a global pharmaceutical company committed to eye health headquartered in Osaka, Japan have launched